Effectiveness of Large Language Model for Anaesthesia and Procedural Consent
Launched by SINGAPORE GENERAL HOSPITAL · Apr 28, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new tool called PEAR, which is an AI-driven chatbot designed to help patients understand the risks of anaesthesia before surgery. The goal is to see if using this chatbot is more effective than the traditional method of having a doctor explain the risks face-to-face. Many patients struggle to understand anaesthesia information due to language differences, time pressure, or varying communication styles from healthcare providers. By using PEAR, the hope is to improve communication and reduce anxiety for patients going into surgery.
To participate in this trial, you need to be an adult (at least 21 years old) who is scheduled for elective surgery that requires anaesthesia and is classified as having a low to moderate risk (ASA Physical Status I to III). You should be able to communicate in English, Mandarin, Malay, or Tamil and be willing to interact with the PEAR chatbot and complete some questionnaires. However, if you have more severe health issues, cognitive impairments, or if you are undergoing emergency surgery, you won't be able to participate. This study is not yet recruiting participants, but it's an exciting opportunity to help improve how patients learn about anaesthesia risks.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Adults (≥21 years old) undergoing elective surgery requiring anaesthesia
- • Classified as ASA Physical Status I to III
- • Able to provide informed consent
- • Able to communicate effectively in English, Chinese (Mandarin), Malay, or Tamil
- • Willing and able to complete questionnaires and interact with the PEAR chatbot (intervention arm)
- Exclusion Criteria:
- • ASA Physical Status IV or above
- • Cognitive impairment or psychiatric conditions that may limit comprehension or communication
- • Non-literate patients or those unable to understand English, Chinese, Malay, or Tamil
- • Emergency surgery cases
- • Prior participation in the study (to prevent bias)
About Singapore General Hospital
Singapore General Hospital (SGH) is a leading academic medical center in Singapore, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SGH plays a pivotal role in conducting cutting-edge studies that aim to improve patient outcomes and enhance medical knowledge across various specialties. With a strong focus on collaboration and multidisciplinary approaches, SGH leverages its extensive resources and expertise to facilitate rigorous clinical trials, ensuring the highest standards of safety and efficacy in the development of new treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported